4-(4-fluoro-phenoxy)phenylisothiocyanate | 851967-55-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(4-fluoro-phenoxy)phenylisothiocyanate
• 英文别名: 4-(4-Fluoro-phenoxy)-phenylisothiocyanate；1-fluoro-4-(4-isothiocyanatophenoxy)benzene
• CAS: 851967-55-0
• 化学式: C₁₃H₈FNOS
• 分子量: 245.277
• InChiKey: LFVWKGMMTZIMJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4-fluoro-phenoxy)phenylisothiocyanate 在 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (R)-4-{N'-[4-(4-fluorophenoxy)-phenyl]-N''-cyanoguanidino}-5-phenyl-pentanoic acid (2-pyrrolidin-1-yl-ethyl)-amide
  参考文献：
  名称：

  Novel glycine transporter type-2 reuptake inhibitors. Part 2: β- and γ-amino acid derivatives

  摘要：

  Several beta- and gamma-amino acid derivatives were prepared as glycine transport inhibitors and their ability to block the uptake of [C-14]-glycine in COS7 cells transfected with human glycine transporter-2 (hGlyT-2) were evaluated. A range of lipophilic side chains were tolerated in the beta-amino acid series (i.e., Ph, CH2Ph, CH(CH3)(2), and CH2CH(CH3)(2)). In the gamma-amino acid series, minimal differences in potency were observed between the alpha, beta-unsaturated analogs and the corresponding saturated derivatives. In both series, a 4-biphenyl or 4-phenoxyphenyl substituent appended to the urea or cyanogunaidine moiety was necessary for in vitro activity. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.05.043
• 作为产物：
  描述：

  4-(4-氟苯氧基)苯胺 、 N,N'-硫羰基二咪唑 以 二氯甲烷 为溶剂， 反应 2.25h， 以99.8%的产率得到4-(4-fluoro-phenoxy)phenylisothiocyanate
  参考文献：
  名称：

  [EN] GLYT2 MODULATORS
  [FR] MODULATEURS DU GLYT2

  摘要：

  公式I的α-, β-, 和 Ϝ-氨基酸衍生物被披露为选择性GlyT2抑制剂，用于治疗中枢神经系统（CNS）疾病，如肌肉痉挛、耳鸣、癫痫和神经痛。

  公开号：

  WO2005044810A1

文献信息

• [EN] GLYT2 MODULATORS<br/>[FR] MODULATEURS DU GLYT2
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005044810A1

  公开（公告）日：2005-05-19

  α-, β-, and Ϝ-amino acid derivatives of formula I are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain. Formula I

  公式I的α-, β-, 和 Ϝ-氨基酸衍生物被披露为选择性GlyT2抑制剂，用于治疗中枢神经系统（CNS）疾病，如肌肉痉挛、耳鸣、癫痫和神经痛。
• GlyT2 modulators
  申请人：Barclay K. Tristin

  公开号：US20050119245A1

  公开（公告）日：2005-06-02

  Certain α-, β-, and γ-amino acid derivatives are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain.

  某些α、β和γ氨基酸衍生物被披露为选择性GlyT2抑制剂，用于治疗中枢神经系统(CNS)疾病，例如肌肉痉挛、耳鸣、癫痫和神经病痛。
• Novel N(SCF₃)(CF₃)-amines: synthesis, scalability and stability
  作者：Yi Yang、Nathalie Saffon-Merceron、Julien C. Vantourout、Anis Tlili

  DOI：10.1039/d2sc06542h

  日期：——

  We disclosed herein a straightforward strategy for the synthesis of unprecedented N-((trifluoromethyl)thio), N-(trifluoromethyl) amines using a combination of isothiocyanates, a fluoride source and an electrophilic trifluoromethylthiolation reagent.

  我们在此公开了一种利用异硫氰酸酯、氟化源和亲电三氟甲基硫代试剂组合合成前所未有的 N-((三氟甲基)硫)、N-(三氟甲基)胺的直接策略。
• US7202269B2
  申请人：——

  公开号：US7202269B2

  公开（公告）日：2007-04-10
• Novel glycine transporter type-2 reuptake inhibitors. Part 2: β- and γ-amino acid derivatives
  作者：Ronald L Wolin、Alejandro Santillán、Tristin Barclay、Liu Tang、Hariharan Venkatesan、Sandy Wilson、Doo Hyun Lee、Timothy W Lovenberg

  DOI：10.1016/j.bmc.2004.05.043

  日期：2004.8

  Several beta- and gamma-amino acid derivatives were prepared as glycine transport inhibitors and their ability to block the uptake of [C-14]-glycine in COS7 cells transfected with human glycine transporter-2 (hGlyT-2) were evaluated. A range of lipophilic side chains were tolerated in the beta-amino acid series (i.e., Ph, CH2Ph, CH(CH3)(2), and CH2CH(CH3)(2)). In the gamma-amino acid series, minimal differences in potency were observed between the alpha, beta-unsaturated analogs and the corresponding saturated derivatives. In both series, a 4-biphenyl or 4-phenoxyphenyl substituent appended to the urea or cyanogunaidine moiety was necessary for in vitro activity. (C) 2004 Elsevier Ltd. All rights reserved.